242 related articles for article (PubMed ID: 22616825)
1. Clinical features and immunohistochemical expression levels of androgen, estrogen, progesterone and Ki-67 receptors in relationship with gross-total resected meningiomas relapse.
Tao Y; Liang G; Li Z; Wang Y; Wu A; Wang H; Lu Y; Liu Z; Hu G
Br J Neurosurg; 2012 Oct; 26(5):700-4. PubMed ID: 22616825
[TBL] [Abstract][Full Text] [Related]
2. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
Abdelzaher E; El-Gendi SM; Yehya A; Gowil AG
Br J Neurosurg; 2011 Dec; 25(6):707-13. PubMed ID: 20979437
[TBL] [Abstract][Full Text] [Related]
3. Detection of progesterone receptor and the correlation with Ki-67 labeling index in meningiomas.
Mukherjee S; Ghosh SN; Chatterjee U; Chatterjee S
Neurol India; 2011; 59(6):817-22. PubMed ID: 22234191
[TBL] [Abstract][Full Text] [Related]
4. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of aromatase and estrogen, androgen and progesterone receptors in normal and neoplastic human meningeal cells.
Leães CG; Meurer RT; Coutinho LB; Ferreira NP; Pereira-Lima JF; da Costa Oliveira M
Neuropathology; 2010 Feb; 30(1):44-9. PubMed ID: 19703265
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone (GnRH) and its receptor in human meningiomas.
Hirota Y; Tachibana O; Uchiyama N; Hayashi Y; Nakada M; Kita D; Watanabe T; Higashi R; Hamada J; Hayashi Y
Clin Neurol Neurosurg; 2009 Feb; 111(2):127-33. PubMed ID: 18980792
[TBL] [Abstract][Full Text] [Related]
7. Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression.
Korhonen K; Salminen T; Raitanen J; Auvinen A; Isola J; Haapasalo H
J Neurooncol; 2006 Oct; 80(1):1-7. PubMed ID: 16703453
[TBL] [Abstract][Full Text] [Related]
8. PCNA, Ki-67 and hTERT in residual benign meningiomas.
Maes L; Kalala JP; Cornelissen M; De Ridder L
In Vivo; 2006; 20(2):271-5. PubMed ID: 16634530
[TBL] [Abstract][Full Text] [Related]
9. Primary resected meningiomas: relapses and proliferation markers.
Kalala JP; Caemaert J; De Ridder L
In Vivo; 2004; 18(4):411-6. PubMed ID: 15369177
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological characteristics, hormone receptor status and matrix metallo-proteinase-9 (MMP-9) immunohistochemical expression in spinal meningiomas.
Barresi V; Alafaci C; Caffo M; Barresi G; Tuccari G
Pathol Res Pract; 2012 Jun; 208(6):350-5. PubMed ID: 22494536
[TBL] [Abstract][Full Text] [Related]
12. Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS
Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of apoptosis regulating proteins and sex hormone receptors in meningiomas.
Takei H; Buckleair LW; Powell SZ
Neuropathology; 2008 Feb; 28(1):62-8. PubMed ID: 18021195
[TBL] [Abstract][Full Text] [Related]
14. Does protein expression predict recurrence of benign World Health Organization grade I meningioma?
Kärjä V; Sandell PJ; Kauppinen T; Alafuzoff I
Hum Pathol; 2010 Feb; 41(2):199-207. PubMed ID: 19801161
[TBL] [Abstract][Full Text] [Related]
15. Expression of progestrone receptor and proliferative marker ki 67 in various grades of meningioma.
Shayanfar N; Mashayekh M; Mohammadpour M
Acta Med Iran; 2010; 48(3):142-7. PubMed ID: 21137648
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
17. Is progesteron receptor status really a prognostic factor for intracranial meningiomas?
Iplikcioglu AC; Hatiboglu MA; Ozek E; Ozcan D
Clin Neurol Neurosurg; 2014 Sep; 124():119-22. PubMed ID: 25036873
[TBL] [Abstract][Full Text] [Related]
18. [Immunohistochemical expression of progesterone receptor in relationship with histological grade and risk of relapses in intracranial meningiomas].
Hernández Faraco A; Céspedes G; Trejo E
Neurologia; 2009 May; 24(4):235-44. PubMed ID: 19603293
[TBL] [Abstract][Full Text] [Related]
19. Significance of COX-2 and VEGF expression in histopathologic grading and invasiveness of meningiomas.
Lee SH; Lee YS; Hong YG; Kang CS
APMIS; 2014 Jan; 122(1):16-24. PubMed ID: 23756256
[TBL] [Abstract][Full Text] [Related]
20. Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors.
Maiuri F; De Caro MB; Esposito F; Cappabianca P; Strazzullo V; Pettinato G; de Divitiis E
J Neurooncol; 2007 Mar; 82(1):63-8. PubMed ID: 17225937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
